Schematic representation of the leptin-melanocortin pathway in the hypothalamic nuclei.

Current Treatments for Patients with Genetic Obesity
Faccioli N et al.
Page: 108-119
AIMS AND SCOPE

The Journal of Clinical Research in Pediatric Endocrinology (JCRPE) publishes original research articles, reviews, short communications, letters, case reports and other special features related to the field of pediatric endocrinology. JCRPE is published in English by the Turkish Society for Pediatric Endocrinology and Diabetes quarterly (March, June, September, December). The target audience is physicians, researchers and other healthcare professionals in all areas of pediatric endocrinology.

JCRPE is indexed in PubMed/MEDLINE, Index Medicus/PubMed, PubMed Central (PMC), British Library, EBSCO, SCOPUS, EMBASE, Engineering Village, Reaxys, Index Copernicus, CINAHL, ProQuest, GALE, Turk Medline, Tübitak Ulakbim TR Index, Turkiye Citation Index, Science Citation Index-SCIE, Hinari, GOALI, ARDI, OARE, AGORA, J-GATE, IdealOnline and DOAJ.


The journal is printed on an acid-free paper.

Permissions

Requests for permission to reproduce published material should be sent to the publisher.

Galenos Publishing House
Address: Molla Gürani mah. Kaçamak Sok. 21/1 Fatih, Istanbul, Turkey
Telephone: +90 212 621 99 25
Fax: +90 212 621 99 27
E-mail: info@galenos.com.tr

Copyright Notice

The author(s) hereby affirms that the manuscript submitted is original, that all statement asserted as facts are based on author(s) careful investigation and research for accuracy, that the manuscript does not, in whole or part, infringe any copyright, that it has not been published in total or in part and is not being submitted or considered for publication in total or in part elsewhere. Completed Copyright Assignment & Affirmation of Originality Form will be faxed to the JCRPE Editorial Office (Fax: +90 212 621 99 27).

By signing this form,
1. Each author acknowledge that he/she participated in the work in a substantive way and is prepared to take public responsibility for the work.
2. Each author further affirms that he or she has read and understands the “Ethical Guidelines for Publication of Research”.
3. The author(s), in consideration of the acceptance of the manuscript for publication, does hereby assign and transfer to the Journal of Clinical Research in Pediatric Endocrinology all of the rights and interest in and the copyright of the work in its current form and in any form subsequently revised for publication and/or electronic dissemination.

Open Access Policy

This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

GENERAL INFORMATION

Manuscripts must be written in English and must meet the requirements of the journal. Papers that do not meet these requirements will be returned to the author for necessary revision before the review. Manuscripts submitted to JCRPE are evaluated by peer reviewers. Authors of manuscripts requiring modifications have two months to resubmit a revised paper. Manuscripts returned after this deadline will be treated as new submissions. The journal is in compliance with the uniform requirements for manuscripts submitted to biomedical journals published by the International Committee of Medical Journal Editors (NEJM 1997; 336:309-315, updated 2001). Upon submission of the manuscript, authors are to indicate the type of trial/research and provide the checklist of the following guidelines when appropriate: Consort statement for randomized controlled trials (Moher D, Schulz KF, Altman D, for the CONSORT Group. The CONSORT statement revised recommendations for improving the quality of reports of parallel group randomized trials. JAMA 2001; 285 : 1987 - 91), the QUOROM statement for meta-analysis and systematic reviews of randomized controlled trials (Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement. Quality of Reporting of Meta-Analyses. Lancet 1999; 354 : 1896 – 900) and the MOOSE guidelines for meta-analysis and systematic reviews of observational studies (Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 2000; 283 : 2008 – 12). Keywords are included according to MeSH (Medical Subject Headings) National Library of Medicine.

Once the manuscript is accepted to be published in The Journal of Clinical Research in Pediatric Endocrinology, it receives a Digital Object Identifier (DOI) number. Uncorrected full text files can be reached online via PubMed and Ahead of Print section of the journal’s website (http://www.jcrpe.org/ahead-of-print). All contents will be printed in black and white.

NEW

Article Publication Charges for accepted case reports is $100. Please contact the editorial office for detailed information by the following link:
info@jcrpe.org

In case of exceeding 4000 word limit, the author is charged with $50 for each page.

All other forms of articles are free of publication charge.

MANUSCRIPT CATEGORIES

All manuscripts must adhere to the limitations, as described below, for text only; the word count does not include the abstract, references, or figure/ table legends. The word count must be noted on the title page, along with the number of figures and tables. Original Articles should be no longer than 4000 words and include no more than six figures and tables and 50 references. Short Communications are short descriptions of focused studies with important, but very straightforward results. These manuscripts should be no longer than 2000 words, and include no more than two figures and tables and 20 references. Brief Reports are discrete, highly significant findings reported in a shorter format. The abstract of the article should not exceed 150 words and the text/ article length should not exceed 1200 words. References should be limited to 12, a maximum of 2 figures or tables.

Clinical Reviews address important topics in the field of pediatric endocrinology. Authors considering the submission of uninvited reviews should contact the editors in advance to determine if the topic that they propose is of current potential interest to the Journal. Reviews will be considered for publication only if they are written by authors who have at least three published manuscripts in the international peer reviewed journals and these studies should be cited in the review. Otherwise only invited reviews will be considered for peer review from qualified experts in the area. These manuscripts should be no longer than 5000 words and include no more than five figures and tables and 120 references.

Case Reports are descriptions of a case or small number of cases revealing novel and important insights into a condition's pathogenesis, presentation, and/or management. These manuscripts should be 2500 words or less, with four or fewer figures and tables and 30 or fewer references.

Consensus Statements may be submitted by professional societies. All such submission will be subjected to peer review, must be modificable in
INSTRUCTIONS TO AUTHORS

MANUSCRIPT PREPARATION

General Format
The Journal requires that all submissions be submitted according to these guidelines:
- Text should be double spaced with 2.5 cm margins on both sides using 12-point type in Times Roman font.
- All tables and figures must be placed after the text and must be labeled.
- Each section (abstract, text, references, tables, figures) should start on a separate page.
- Manuscripts should be prepared as word document (*.doc) or rich text format (*.rtf).

Title Page
The title page should include the following:
- Full title
- Short title of not more than 40 characters for page headings
- Authors’ names, and institutions, and e-mail addresses
- Corresponding author’s e-mail and post address, telephone and fax numbers
- At least five and maximum eight keywords. Do not use abbreviations in the keywords
- Word count (excluding abstract, figure legends and references)
- Name and address of person to whom reprint requests should be addressed
- Any grants or fellowships supporting the writing of the paper
- The acknowledgements, if there are any
- If the content of the manuscript has been presented before, the time and place of the presentation
- The ORCID (Open Researcher and Contributor ID) number of all authors should be provided while sending the manuscript. A free registration can be done at http://orcid.org.

Structured Abstracts (According to the The Journal of the American Medical Association)
Original Articles should be submitted with structured abstracts of no more than 250 words. All information reported in the abstract must appear in the manuscript. The abstract should not include references. Please use complete sentences for all sections of the abstract. Structured abstract should include background, objective, methods, results and conclusion.

What is already known on this topic?
What this study adds?

Introduction
The article should begin with a brief introduction stating why the study was undertaken within the context of previous reports.

Experimental Subjects
All clinical investigations described in submitted manuscripts must have been conducted in accordance with the guidelines in the Declaration of Helsinki and has been formally approved by the appropriate institutional review committees. All manuscripts must indicate that such approval was obtained and that informed consent was obtained from subjects in all experiments involving humans. The study populations should be described in detail. Subjects must be identified only by number or letter, not by initials or names. Photographs of patients’ faces should be included only if scientifically relevant. Authors must obtain written consent from the patient for use of such photographs.

Clinical Trials Registration
For clinical trial reports to be considered for publication in the Journal, prospective registration, as endorsed by the International Conference of Medical Journal Editors, is required. We recommend use of http://www.clinicaltrials.gov.

Experimental Animals
A statement confirming that all animal experimentation described in the submitted manuscript was conducted in accord with accepted standards of

Note on Prior Publication
The Journal publishes original research and review material. Material previously published in whole or in part shall not be considered for publication. At the time of submission, authors must report that the manuscript has not been published elsewhere. Abstracts or posters displayed at scientific meetings need not be reported.

MANUSCRIPT SUBMISSION PROCEDURES
JCRPE only accepts electronic manuscript submission at the web site www.jcrpe.org
After logging on to the website www.jcrpe.org click ‘online manuscript submission’ icon. All corresponding authors should be provided a password and a username after providing the information needed. If you already have an account from a previous submission, enter your username and password to submit a new or revised manuscript. If you have forgotten your username and/or password, e-mail the editorial office for assistance. After logging on the article submission system with your own password and username please read carefully the directions of the system to provide all needed information. Attach the manuscript, tables and figures and additional documents.

All Submissions Must Include:
1. A cover letter requesting that the manuscript be evaluated for publication in JCRPE and any information relevant to your manuscript. Cover letter should contain address, telephone, fax and e-mail address of the corresponding author.

2. Completed Copyright and Disclosure of Potential Conflicts of Interest Form. The corresponding author must acquire all of the authors’ completed forms and mail to info@galenos.com.tr / yayin@galenos.com.tr or submit to the Manuscript Manager.

3. Completed Disclosure of Potential Conflict of Interest Form. The corresponding author must acquire all of the authors’ completed disclosure forms and fax them to the editorial office at +90 212 621 99 27.

Authors must complete the online submission forms. If unable to successfully upload the files please contact the editorial office by e-mail.

INSTRUCTIONS TO AUTHORS
humane animal care, according to the Declaration of Helsinki and Genova Convention, should be included in the manuscript.

**Materials and Methods**
These should be described and referenced in sufficient detail for other investigators to repeat the work. Ethical consent should be included as stated above.

The name of the ethical committee, approval number should be stated. At the same time, the Ethics Committee Approval Form should be uploaded with the article.

**Results**
The Results section should briefly present the experimental data in text, tables, and/or figures. Do not compare your observations with that of others in the results section.

The raw results of weight, length/height, body mass index, and blood pressure measurements can not be compared among groups since they normally change with age and according to gender. Instead, standard deviation scores of those values should be reported and compared.

**Discussion**
The Discussion should focus on the interpretation and significance of the findings with concise objective comments that describe their relation to other work in that area and contain study limitations.

**Study Limitations**
Limitations of the study should be detailed. In addition, an evaluation of the implications of the obtained findings/results for future research should be outlined.

**Conclusion**
The conclusion of the study should be highlighted.

**Acknowledgments (Not Required for Submission)**
An acknowledgment is given for contributors who may not be listed as authors, or for grant support of the research.

**Authorship Contribution**
The kind of contribution of each author should be stated.

**References**
References to the literature should be cited in numerical order (in parentheses) in the text and listed in the same numerical order at the end of the manuscript on a separate page or pages. The author is responsible for the accuracy of references.

Number of References: Case Report max 30 / Original Articles max 50
Examples of the reference style are given below. Further examples will be found in the articles describing the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (Ann Intern Med. 1988; 208:258-265, Br Med J. 1988; 296:401-405). The titles of journals should be abbreviated according to the style used in the Index Medicus.

Journal Articles and Abstracts: List all authors. The citation of unpublished observations, of personal communications is not permitted in the bibliography. The citation of manuscripts in press (i.e., accepted for publication) is permitted in the bibliography; the name of the journal in which they appear must be supplied. Citing an abstract is not recommended.

Books: List all authors or editors.

**Sample References**

**Papers Published in Periodical Journals:**

**Tables**
Tables must be constructed as simply as possible. Each table must have a concise heading and should be submitted on a separate page. Tables must not simply duplicate the text or figures. Number all tables in the order of their citation in the text. Include a title for each table (a brief phrase, preferably no longer than 10 to 15 words). Include all tables in a single file following the manuscript.

**Figures Legends**
Figure legends and titles should be submitted on a separate page. Figure legends and titles should be clear and informative. Tables and figures should work under “windows”.

Number all figures (graphs, charts, photographs, and illustrations) in the order of their citation in the text. Include a title for each figure (a brief phrase, preferably no longer than 10 to 15 words).

**Figures & Images**
At submission, the following file formats are acceptable: AI, EMF, EPS, JPG, PDF, PPT, PS, PDF. Figures may be embedded at the end of the manuscript text file or loaded as separate files for submission purposes.

All images MUST be at or above intended display size, with the following image resolutions: Line Art 800 dpi, Combination (Line Art + Halftone) 600 dpi, Halftone 300 dpi. See the Image quality specifications chart for details. Image files also must be cropped as close to the actual image as possible.

**Units of Measure**
Results/Tables should be expressed in metric units. If needed please apply this usage in your manuscript.

If p values are significant in the tables you have prepared, the relevant p values should be indicated in bold font.

**Validation of Data and Statistical Analysis**
Assay validation: Bioassay and radioimmunoassay potency estimates should be accompanied by an appropriate measure of the precision of these estimates. For bioassays, these usually will be the standard deviation, standard error of the mean, confidence limits. For both bioassays and radioimmunoassays, it is necessary to include data relating to within-assay and between-assay variability. If all relevant comparisons are made within the same assay, the latter may be omitted. Statistical analysis should be done accurately and with precision. Please consult a statistician if necessary.
Proofs and Reprints
Proofs and a reprint order are sent to the corresponding author. The author should designate by footnote on the title page of the manuscript the name and address of the person to whom reprint requests should be directed. The manuscript when published will become the property of the journal.

Page and Other Charges
Archiving
The editorial office will retain all manuscripts and related documentation (correspondence, reviews, etc.) for 12 months following the date of publication or rejection.

Submission Preparation Checklist
As part of the submission process, authors are required to check off their submission's compliance with all of the following items, and submissions may be returned to authors that do not adhere to these guidelines.

1. The submission has not been previously published, nor is it before another journal for consideration (or an explanation has been provided in Comments to the Editor).
2. The submission file is in Microsoft Word, RTF, or WordPerfect document file format. The text is double-spaced; uses a 12-point font; employs italics, rather than underlining (except with URL addresses); and all illustrations, figures, and tables are placed within the text at the appropriate points, rather than at the end. Please do not send the manuscript in docx.
3. Where available, URLs for the references have been provided.
4. A completed Copyright and Disclosure of Potential Conflicts of Interest Form must be uploaded with other files during the submission. The corresponding author must acquire all of the authors’ completed forms and mail to info@galenos.com.tr / yayin@galenos.com.tr or submit to the Manuscript Manager.
5. The text adheres to the stylistic and bibliographic requirements outlined in the Author Guidelines, which is found in About the Journal.
6. Completed Disclosure of Potential Conflict of Interest Form. The corresponding author must acquire all of the authors’ completed disclosure forms and fax them, together, to the editorial office along with the Author Disclosure Summary.

Privacy Statement
The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.

Peer Review Process
1. The manuscript is assigned to an editor, who reviews the manuscript and makes an initial decision based on manuscript quality and editorial priorities.
2. For those manuscripts sent for external peer review, the editor assigns reviewers to the manuscript.
3. The reviewers review the manuscript.
4. The editor makes a final decision based on editorial priorities, manuscript quality, and reviewer recommendations.
5. The decision letter is sent to the author.

The Reviewer is Asked to Focus on the Following Issues:
1. General recommendation about the manuscript
   How original is the manuscript?
   Is it well presented?
   How long is the manuscript?
2. Publication timing, quality, and priority
   How important is the manuscript in this field?
   Does it present original data?
   Does it carry priority in publishing?
3. Specific questions regarding the quality of the manuscript
   Does the title describe the study accurately?
   Is the abstract informative and clear?
   Are the authors’ questions in the introduction?
   Are the methods clear?
   Are ethical guidelines met?
   Are statistical analyses appropriate?
   Are the results presented clearly?
   Does the discussion cover all of the findings?
   Are the references appropriate for the manuscript?
4. Remarks to the editor
   Accepted in its present form
   Accepted after modest revisions
   Reconsidered for acceptance after major changes
   Rejected
5. Remarks to the author
   What would be your recommendations to the author?
   Conflict of interest statement for the reviewer (Please state if a conflict of interest is present)
For further instructions about how to review, see Reviewing Manuscripts for Archives of Pediatrics & Adolescent Medicine by Peter Cummings, MD, MPH; Frederick P. Rivara, MD, MPH in Arch Pediatr Adolesc Med. 2002;156:11-13.
Tüm temel endikasyonlarda onaylı tek sivi büyüme hormonu

**ADANMİŞLIK**

- Kullanım kolaylığı
- Onaylı uzun dönem etkiliğinin sürekliliği
- Uygunluk
- Kullanma hazır sıvı formlarının oluşumunun mümkün olduğu
- Kanitlanmış güvenilirlik
- Yılların biyoteknoloji deneyiminde

---

Referanslar:

Bu açıdan izleme tabidir. Bu açıdan yeni endikasyonlar bulunmadı.

---

**Üyelik ve tedavi süresi**

- Dozaj ve tedavi süresi hastanın tedaviye vereceği yanıta göre bireyselleştirilmelidir.
- Uygulama şekli: Subkütan kullanım için özel olarak geliştirilmiş bir enjeksiyon aracı (enjeksiyon kalemi) olan SurePal™ 5; OMNİTROPE® 10 mg (30 15 mg/1,5 mL OMNİTROPE®'un 5 mg subkütan enjeksiyonundan sonra Cmaks ve tmaks değerleri sırasıyla 52 ± 19 mikrogram/L ve 4 ± 2 saattir. Örneğin, enjeksiyon kaleminden 20 mL suyi hâkim olmak için 30-15 mg eylem fazlası eklenir.
- OMNİTROPE® ve OMNİTROPE® 10 mg (30 15 mg/1,5 mL) form her mL'de 9 mg benzil alkol içerir. Benzil alkol varlığında toksik reaksiyonlara ve anaflaktoid reaksiyonlara sebebiyet verebilir. Gebelik ve hamilelik periodinde kullanılmamalıdır. OMNİTROPE® ve OMNİTROPE® 10 mg (30 15 mg/1,5 mL) form her mL'de 9 mg benzil alkol içerir. Benzil alkol varlığında toksik reaksiyonlara ve anaflaktoid reaksiyonlara sebebiyet verebilir. Gebelik ve hamilelik periodinde kullanılmamalıdır. OMNİTROPE® ve OMNİTROPE® 10 mg (30 15 mg/1,5 mL) form her mL'de 9 mg benzil alkol içerir. Benzil alkol varlığında toksik reaksiyonlara ve anaflaktoid reaksiyonlara sebebiyet verebilir. Gebelik ve hamilelik periodinde kullanılmamalıdır. OMNİTROPE® ve OMNİTROPE® 10 mg (30 15 mg/1,5 mL) form her mL'de 9 mg benzil alkol içerir. Benzil alkol varlığında toksik reaksiyonlara ve anaflaktoid reaksiyonlara sebebiyet verebilir. Gebelik ve hamilelik periodinde kullanılmamalıdır. OMNİTROPE® ve OMNİTROPE® 10 mg (30 15 mg/1,5 mL) form her mL'de 9 mg benzil alkol içerir. Benzil alkol varlığında toksik reaksiyonlara ve anaflaktoid reaksiyonlara sebebiyet verebilir. Gebelik ve hamilelik periodinde kullanılmamalıdır. OMNİTROPE® ve OMNİTROPE® 10 mg (30 15 mg/1,5 mL) form her mL'de 9 mg benzil alkol içerir. Benzil alkol varlığında toksik reaksiyonlara ve anaflaktoid reaksiyonlara sebebiyet verebilir. Gebelik ve hamilelik periodinde kullanılmamalıdır. OMNİTROPE® ve OMNİTROPE® 10 mg (30 15 mg/1,5 mL) form her mL'de 9 mg benzil alkol içerir. Benzil alkol varlığında toksik reaksiyonlara ve anaflaktoid reaksiyonlara sebebiyet verebilir. Gebelik ve hamilelik periodinde kullanılmamalıdır. OMNİTROPE® ve OMNİTROPE® 10 mg (30 15 mg/1,5 mL) form her mL'de 9 mg benzil alkol içerir. Benzil alkol varlığında toksik reaksiyonlara ve anaflaktoid reaksiyonlara sebebiyet verebilir. Gebelik ve hamilelik periodinde kullanılmamalıdır. OMNİTROPE® ve OMNİTROPE® 10 mg (30 15 mg/1,5 mL) form her mL'de 9 mg benzil alkol içerir. Benzil alkol varlığında toksik reaksiyonlara ve anaflaktoid reaksiyonlara sebebiyet verebilir. Gebelik ve hamilelik periodinde kullanılmamalıdır. OMNİTROPE® ve OMNİTROPE® 10 mg (30 15 mg/1,5 mL) form her mL'de 9 mg benzil alkol içerir. Benzil alkol varlığında toksik reaksiyonlara ve anaflaktoid reaksiyonlara sebebiyet verebilir. Gebelik ve hamilelik periodinde kullanılmamalıdır. OMNİTROPE® ve OMNİTROPE® 10 mg (30 15 mg/1,5 mL) form her mL'de 9 mg benzil alkol içerir. Benzil alkol varlığında toksik reaksiyonlara ve anaflaktoid reaksiyonlara sebebiyet verebilir. Gebelik ve hamilelik periodinde kullanılmamalıdır. OMNİTROPE® ve OMNİTROPE® 10 mg (30 15 mg/1,5 mL) form her mL'de 9 mg benzil alkol içerir. Benzil alkol varlığında toksik reaksiyonlara ve anaflaktoid reaksiyonlara sebebiyet verebilir. Gebelik ve hamilelik periodinde kullanılmamalıdır. OMNİTROPE® ve OMNİTROPE® 10 mg (30 15 mg/1,5 mL) form her mL'de 9 mg benzil alkol içerir. Benzil alkol varlığında toksik reaksiyonlara ve anaflaktoid reaksiyonlara sebebiyet verebilir. Gebelik ve hamilelik periodinde kullanılmamalıdır. OMNİTROPE® ve OMNİTROPE® 10 mg (30 15 mg/1,5 mL) form her mL'de 9 mg benzil alkol içerir. Benzil alkol varlığında toksik reaksiyonlara ve anaflaktoid reaksiyonlara sebebiyet verebilir. Gebelik ve hamilelik periodinde kullanılmamalıdır. OMNİTROPE® ve OMNİTROPE® 10 mg (30 15 mg/1,5 mL) form her mL'de 9 mg benzil alkol içerir. Benzil alkol varlığında toksik reaksiyonlara ve anaflaktoid reaksiyonlara sebebiyet verebilir. Gebelik ve hamilelik periodinde kullanılmamalıdır. OMNİTROPE® ve OMNİTROPE® 10 mg (30 15 mg/1,5 mL) form her mL'de 9 mg benzil alkol içerir. Benzil alkol varlığında toksik reaksiyonlara ve anaflaktoid reaksiyonlara sebebiyet verebilir. Gebelik ve hamilelik periodinde kullanılmamalıdır. OMNİTROPE® ve OMNİTROPE® 10 mg (30 15 mg/1,5 mL) form her mL'de 9 mg benzil alkol içerir. Benzil alkol varlığında toksik reaksiyonlara ve anaflaktoid reaksiyonlara sebebiyet verebilir. Gebelik ve hamilelik periodinde kullanılmamalıdır. OMNİTROPE® ve OMNİTROPE® 10 mg (30 15 mg/1,5 mL) form her mL'de 9 mg benzil alkol içerir. Benzil alkol varlığında toksik reaksiyonlara ve anaflaktoid reaksiyonlara sebebiyet verebilir. Gebelik ve hamilelik periodinde kullanılmamalıdır. OMNİTROPE® ve OMNİTROPE® 10 mg (30 15 mg/1,5 mL) form her mL'de 9 mg benzil alkol içerir. Benzil alkol varlığında toksik reaksiyonlara ve anaflaktoid reaksiyonlara sebebiyet verebilir. Gebelik ve hamilelik periodinde kullanılmamalıdır. OMNİTROPE® ve OMNİTROPE® 10 mg (30 15 mg/1,5 mL) form her mL'de 9 mg benzil alkol içerir. Benzil alkol varlığında toksik reaksiyonlara ve anaflaktoid reaksiyonlara sebebiyet verebilir. Gebelik ve hamilelik periodinde kullanılmamalıdır. OMNİTROPE® ve OMNİTROPE® 10 mg (30 15 mg/1,5 mL) form her mL'de 9 mg benzil alkol içerir. Benzil alkol varlığında toksik reaksiyonlara ve anaflaktoid reaksiyonlara sebebiyet verebilir. Gebelik ve hamilelik periodinde kullanılmamalıdır. OMNİTROPE® ve OMNİTROPE® 10 mg (30 15 mg/1,5 mL) form her mL'de 9 mg benzil alkol içerir. Benzil alkol varlığında toksik reaksiyonlara ve anaflaktoid reaksiyonlara sebebiyet verebilir. Gebelik ve hamilelik periodinde kullanılmamalı...
Reviews

108 Current Treatments for Patients with Genetic Obesity
Nathan Faccioli, Christine Poitou, Karine Clément, Béatrice Dubern

120 Frequently Asked Questions and Evidence-Based Answers on Medical Nutritional Therapy in Children with Type 1 Diabetes for Health Care Professionals
Beyza Eliuz Tipici, Yasemin Atik Altınok, Alev Keser

Original Articles

127 The Importance of Extended High Frequencies in Hearing Evaluation of Pediatric Patients with Type 1 Diabetes
Selis Gülseven Güven, Cığdem Binay

138 Novel Modified Algorithm for High Fat/High Energy Density Meal in Type 1 Diabetes: Less Hypoglycemia
Yasemin Atik Altınok, Günay Demir, Hafize Çetin, Samim Özen, Şükran Darcan, Damla Gökşen

145 Evaluation of The Effects of Carob (Ceratonia siliqua L.) Fruits on the Puberty of Rats
Aylin Kilinc Uğurlu, Aysun Bideci, Elvan Anadol, Ipek Sünar, Gülnur Take Kaplanoglu, Özlem Gülbahar, Zeynep Şafak Teksin, Duygu Dayanır, Tuba Saadet Deveci Bulut, Canan Uluoğlu, M. Orhun Camurdan

154 Decline in the Age of Menarche in Istanbul Schoolgirls Over the Last 12 Years

160 Clinical Characteristics and Genetic Analyses of Patients with Idiopathic Hypogonadotropic Hypogonadism
Nurdan Çiftci, Ayşehan Akıncı, Ekrem Akbulut, Emine Camtösun, İsmail Dündar, Mustafa Doğan, Leman Kayas

172 Chronic Disease Management of Children Followed with Type 1 Diabetes Mellitus
Şenay Güven Baysal, Nurdan Çiftci, İsmail Dündar, Mehmet Akif Büyükavcı, Fatma Hilal Yaşın, Emine Camtösun, Derya Gümüş Doğan, Ayşehan Akıncı

182 Comparison of Makorin Ring Finger Protein 3 Levels Between Obese and Normal Weight Patients with Central Precocious Puberty
Sümeyye Emel Eren, Emre Simşek

190 Can Serum 25-Hydroxy Vitamin D Levels Predict the Severity of Multisystem Inflammatory Syndrome in Children and COVID-19?
Yıldız Ekemen Keles, Dilek Yılmaz, Selin Tasar, Gülnihan Üstündağ, Aslıhan Sahin, Aysegül Elvan Tuz, Aslıhan Arslan Maden, Ahu Kara Aksay, Ayfer Colak, Eda Karadağ Öncel

Case Reports

199 Primary Thyroid Diffuse Large B-cell Lymphoma in a Child with Hashimoto’s Thyroiditis: A Case Report
Maria Katzipsalti, Evangelos Bourousis, Maria Nikita, Dimitra Rontogianni, Myrsini. G. Gkeli, Dionisios Chrysos, Aristeidis Giannakopoulos, Dimitrios Delis, Margarita Baka, Andriani Vazeou
205  Prolyl Endopeptidase-like Deficiency Associated with Growth Hormone Deficiency
Laura Sayol-Torres, Maria Irene Valenzuela, Rosangela Tomasini, Paula Fernández-Alvarez, Maria Clemente, Diego Yeste

210  A Potentially Fatal Outcome of Oral Contraceptive Therapy: Estrogen-Triggered Hereditary Angioedema in an Adolescent
Uğur Berkay Balkancı, Demet Demirkol, Gül Yesiltepe Mutlu, Esra Birben, Özge Soyer, Özlem Yılmaz, Cansın Sackesen

214  Nephrogenic Syndrome of Inappropriate Antidiuresis Mimicking Hyporeninemic Hypoaldosteronism: Case Report of Two Infants
Jamala Mammadova, Cengiz Kara, Eda Celebi Bitkin, Elif İzci Güllo, Murat Aydın

220  An Alternative Route of Treatment in Transient Hypothyroxinemia of Prematurity: Rectal Administration of Levothyroxine
Duygu Tuncel, Zeynep İnce, Erhan Aygün, Asuman Coban

225  Liraglutide Treatment in a Morbidly Obese Adolescent with a MC4R Gene Variant: Side Effects Reduce Success
Emine Çamtosun, Ayşehan Akınçi, Leman Kayas, Nurdan Çiftçi, İbrahim Tekedereli